Avinger (NASDAQ:AVGR) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Avinger (NASDAQ:AVGR) in a research note released on Monday morning. The firm issued a hold rating on the medical device company’s stock.

Avinger Price Performance

Shares of NASDAQ AVGR opened at $0.75 on Monday. The company has a market cap of $2.41 million, a PE ratio of -0.07 and a beta of 1.15. Avinger has a 12 month low of $0.70 and a 12 month high of $5.45. The company has a 50-day simple moving average of $0.92 and a 200-day simple moving average of $1.54.

Avinger (NASDAQ:AVGR) last released its earnings results on Thursday, November 7th. The medical device company reported ($1.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.21. Avinger had a negative net margin of 261.06% and a negative return on equity of 5,527.11%. The business had revenue of $1.65 million for the quarter, compared to analysts’ expectations of $1.60 million. During the same period last year, the company earned ($2.92) earnings per share. On average, analysts anticipate that Avinger will post -4.69 EPS for the current year.

Institutional Trading of Avinger

An institutional investor recently bought a new position in Avinger stock. Armistice Capital LLC bought a new stake in shares of Avinger, Inc. (NASDAQ:AVGR) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 43,747 shares of the medical device company’s stock, valued at approximately $81,000. Armistice Capital LLC owned about 2.57% of Avinger at the end of the most recent reporting period. 18.30% of the stock is currently owned by institutional investors.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.